Currently, one clinical trial is using SaCas9 and delivery by AAV into the retina to treat Type 10 Leber congenital amaurosis (LCA10), a severe retinal dystrophy caused by mutations in the CEP290 gene, by removing the aberrant splice donor created by the IVS26 mutation and thereby restoring normal CEP290 expression 185. The gene discussed is CEP290; the disease is inherited retinal dystrophy.